Cite

    Halloush, S. et al. (2022). Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Current medical research and opinion. pp. 571-577. [Online].